The Cytel Blog: Perspectives on Enquiry & Evidence

Cytel’s HEOR and RWE Expertise has grown quite significantly in the past year. Could you speak a little bit about the..

Cytel’s team of HEOR and RWE experts are all set to make a splash at the Virtual ISPOR on May 17 - 20. Our global..

After twenty years in pharma, Anna Forsythe was frustrated by traditional vendors who used outdated methods to prepare..

Virtual ISPOR 2020, held November 16 to 19, presented new opportunities for scientific interaction amongst HEOR..

In oncology, many manufacturers go into niche indications, where there are very specific tumors, and then they opt for..

In this two-part blog series, we interview Bart Heeg, Vice President HEOR and Founder at Ingress Health (A Cytel..

In this interview with Thomas Wilke, Principal Scientist at Ingress-Health (a Cytel company), we talk to him about his..

A credible evidence base is needed to support and document the economic value of new technologies and therapeutic..

The combination of greater access to electronic health records, bigger electronic claims datasets, and the need for..